Cibus (CBUS)
NASDAQ:CBUS
Want to see CBUS full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.61Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized execution: material commercial progress in LATAM rice (LOI, import permit, delivery of edited materials), clear technical advances (order-of-magnitude improvement in editing efficiency; wheat single-cell regeneration), regulatory tailwinds, and tangible cost reductions that materially improved the P&L and extended runway after raising ~ $37M gross. Offsets include a limited cash runway into Q1 2027 absent stronger near-term revenue, a U.S. rice launch delay from 2028 to 2029 due to herbicide registration timing, continued sizable quarterly net losses and interest on royalty liabilities, and several commercial arrangements still at LOI or early stages. Overall, the positives (capital raise, execution on priority programs, technical and regulatory momentum, and meaningful expense reductions) outweigh the negatives, though the company's trajectory remains execution-dependent.Company Guidance
Significant Capital Raised and Improved Runway
Raised approximately $37 million in gross proceeds across two public offerings ($22.3M in January and ~ $15M in March); cash and cash equivalents of $30.3M as of March 31, 2026. Management expects existing cash plus cost-savings to fund operations into late Q1 2027.
Material Reduction in Operating Expenses and Net Loss
Combined operating expenses declined by nearly $8.0M year-over-year. R&D expense fell from $11.8M to $8.7M (down ~$3.1M, ~26% YoY) and SG&A fell from $9.9M to $5.1M (down ~$4.8M, ~49% YoY). Net loss improved from $49.4M to $21.2M (improvement of ~$28.2M, ~57% reduction); net loss per Class A share improved from $1.34 to $0.33 (down ~$1.01, ~75%). Management targets annual net cash usage of ~$30M or less for 2026.
Commercial Progress in Rice Program (LATAM Focus)
Executed nonbinding LOI with Interoc establishing commercialization framework for herbicide-tolerant rice in LATAM (targeting Ecuador and Colombia in 2027 with phased expansion into Peru, Central America and Caribbean). Interoc received an import permit in March enabling transfers; completed delivery of gene-edited HT rice materials in May. Company reports 7 active rice seed company relationships across LATAM and U.S., and is on track for planned 2027 initial LATAM commercial launch.
Sustainable Ingredients Moving Toward Commercial Scale
Sustainable Ingredients program validated through pre-commercial pilot runs and prior customer payments; recognized a catch-up customer payment in Q1. Program in commercial ramp-up with expected additional scale-up orders of initial biofragrances in H2 2026. Company estimates global fragrance market > $65B and potential $20M–$40M annual royalty opportunity when fully commercialized.
Technical and Platform Advances
Achieved an order-of-magnitude improvement in rice editing efficiency through optimization and AI/ML application, enabling higher throughput. Single-cell regeneration achieved in a wheat cultivar, opening wheat trait development. Continued progress on soybean HT2, DEFRA-funded canola Light Leaf Spot work underway (initial funding expected 2026), and Pod Shatter Reduction advancing to U.K. plantings under Precision Bred Organisms framework.
Regulatory Momentum and Approvals
Regulatory tailwinds include 17 positive USDA-APHIS determinations in the U.S.; Ecuador and Peru determined HT1/HT3 rice traits equivalent to conventional breeding; EU New Genomic Techniques legislation advancing (ENVI and Commission support), improving commercial clarity across key jurisdictions.
CBUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CBUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $1.41 | $1.31 | -7.09% |
Mar 17, 2026 | $3.68 | $2.77 | -24.73% |
Nov 13, 2025 | $1.25 | $1.22 | -2.40% |
Aug 14, 2025 | $1.47 | $1.41 | -4.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cibus (CBUS) report earnings?
Cibus (CBUS) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Cibus (CBUS) earnings time?
Cibus (CBUS) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CBUS EPS forecast?
CBUS EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.